Roche Strengthens Its Bet Against the “Superbug”By Ion Jauregui – Analyst at ActivTrades
Zosurabalpin: A New Hope Against Antimicrobial Resistance
Swiss pharmaceutical giant Roche (SWX: ROG) has just taken a major step forward in the fight against bacterial resistance: its new antibiotic zosurabalpin is entering Phase 3 clinical trials. The co
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
1.455 EUR
9.08 B EUR
66.36 B EUR
5.52 B
About Roche Holding Ltd
Sector
Industry
CEO
Thomas Schinecker
Website
Headquarters
Basel
Founded
1896
ISIN
US7711951043
FIGI
BBG00SJ39591
Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics, and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.
Related stocks
Roche vs. Novo Nordisk: Who will suffer the Weight Loss?Roche (ticker: ROG.SW) is losing ground on the stock due to the side effects of its new weight loss pill, CT-996, which is still in the testing phase. After a rally that boosted its shares 40% between May and September, the Swiss drugmaker has seen an 11% drop in its shares in September alone, inclu
Roche Analysis 6/26DISCLOSURE: as of 6/26 I have no open position in SIX:RO
Roche is a Swiss based pharmaceutical conglomerate with a diverse range of operations and brands. The company has a long history of profitability and high returns on investment.
Management Effectiveness: Roche has been around since 1896
Roche: Ready for 120% Growth?We're trying something with Roche here, where we think that we are currently in Wave (5), having recently completed Wave (4). This assessment is better visualized on the daily chart. Hence, we should maintain the 61.8% level for this Wave 4. Anything below would statistically be too low, while above
Hold it like a rock - Roche, what an opportunity.Hi, 1PERCENT here.
Roche Holding, a Swiss multinational biopharma company. It is like the Apple of biopharma.
There were only 3 pull backs greater than 30% in the history of the stock.
2002 ~ 2003: -45.33%
2006 ~ 2011: -52.40%
2014 ~ 2018: -30.24%
2022 ~ present: -44.89%
It is at the support z
Roche HoldingsThis is one of those companies you can't afford not to look into. Roche is one of the world's largest biotech companies and a global leader in pharmaceuticals and diagnostics. This leading position translates to strong market share, revenue, and profitability. The company operates across various seg
See all ideas
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
CHGCY5885610
Roche Holdings, Inc. 4.203% 09-SEP-2029Yield to maturity
—
Maturity date
Sep 9, 2029
CHGCY5698748
Roche Holdings, Inc. 5.593% 13-NOV-2033Yield to maturity
—
Maturity date
Nov 13, 2033
A3K2RB
Roche Kapitalmarkt AG 0.75% 25-FEB-2031 2022-25.02.31 GUARANTEED REG SYield to maturity
—
Maturity date
Feb 25, 2031
CHGCY5766486
Roche Holdings, Inc. 5.218% 08-MAR-2054Yield to maturity
—
Maturity date
Mar 8, 2054
CHGCY4307677
Roche Holdings, Inc. 3.0% 10-NOV-2025Yield to maturity
—
Maturity date
Nov 10, 2025
A3K2JZ
Roche Kapitalmarkt AG 0.5% 25-FEB-2027 2022-25.02.27 GUARANTEED REG SYield to maturity
—
Maturity date
Feb 25, 2027
CHGCY5698943
Roche Holdings, Inc. 5.489% 13-NOV-2030Yield to maturity
—
Maturity date
Nov 13, 2030
CHGCY5698948
Roche Holdings, Inc. 5.265% 13-NOV-2026Yield to maturity
—
Maturity date
Nov 13, 2026
A3K2NX
Roche Kapitalmarkt AG 1.0% 25-FEB-2037 2022-25.02.37 GUARANTEED REG SYield to maturity
—
Maturity date
Feb 25, 2037
CHGCY5766479
Roche Holdings, Inc. 4.79% 08-MAR-2029Yield to maturity
—
Maturity date
Mar 8, 2029
CHGCY5766483
Roche Holdings, Inc. 4.985% 08-MAR-2034Yield to maturity
—
Maturity date
Mar 8, 2034
See all RHO6 bonds
Curated watchlists where RHO6 is featured.